D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.
|Videos|January 11, 2012
Dr. Mistry Discusses His Experience With Gaucher Disease
Author(s)Onclive Team
Pramod K. Mistry, MD, PhD, from Yale University, discusses Gaucher disease
Advertisement
Pramod Kumar Mistry, MBBS, PhD, is chief of Pediatric Gastroenterology & Hepatology, medical director of the Pediatric Liver Transplant Program, and a professor of Pediatrics and Internal Medicine at Yale University School of Medicine, New Haven, Conneticut. He also is the director of the National Gaucher Disease Treatment Center.
Advertisement
Related to this article
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
2
Arlo-Cel Meets ORR End Point in BCMA-Pretreated, Quadruple-Class Exposed R/R Myeloma
3
Camidge and Singhi Highlight the Lung Cancer Abstracts to Watch at WCLC 2026
4
Frontline Mipletamig Triplet Drives Clinical Benefit in TP53-Mutated AML
5